Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  11.00 6.4% 183.00 4,093,848 16:35:20
Bid Price Offer Price High Price Low Price Open Price
180.00 183.00 185.00 171.50 171.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.94 -29.19 -10.57 466
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:44 O 20 183.00 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:08:44183.002036.60O
17:06:00183.00178,000325,740.00O
16:54:49171.5264,400110,456.95O
16:53:29179.48174312.30O
16:52:30179.48174312.30O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

Top Posts
Posted at 05/2/2023 14:14 by tickboo
Mislead? Like doxorubicin under patent? Like Avacta has never undertaken animal studies? Avacta will publish interim results late as the auditor will not sign off the accounts due to lack of cash? Like Avacta will not take any biopsies? Like Avacta will not complete the purchase of Launch Diagnostics? Plenty more where they came from but the latest is Avacta will not hold a science day as it was only taking place to support the share price which is no longer needed.What a weird, pathetic little man you are. Get a life. Your life seems to be appearing on BBs when a share price is making large moves. Sad.
Posted at 02/2/2023 08:55 by tickboo
Log wants it over double the last raise price. Funny. We are some 65% above it and he will not sell more. No conviction at all. If he thinks my or anyone else's posts increase or decrease the share price he is beyond naive. Lots of the TA lot called the rise and no ramps needed. I suspect we will be beyond 200p come early March once the details (and RNS beforehand) of the science day are taken in. Emerging data on 6000 showing its following pre-clinical which is superb and of course that unlocks TMAC and we'll get updates on other pre-clinical work. Of course we could get partner news any day too. As I said when the share price was falling I'm more relaxed here than I've ever been.
Posted at 30/1/2023 08:18 by loglorry1
Right @tickboo now I'm really annoyed. I warned you on Friday if I had to come back here and find the share price fallen again even lower I'd be furious. All the hours of ramping you do and still the share price falls. If even 10% of what you said was true the share price would be shooting to the moon. Are you deliberately lying?

I want the share price higher.

Feel free to appologise tickboo at any time!

Posted at 23/1/2023 17:04 by amaniitangelicus
Very impressed with how Avacta have handled the fundraise. Now that is built in to the share price mixed with encouraging news on how the trial is proceeding this share price is going to push to new highs with Science Day coming soon. Very happy with the resilient share price over the last few days. What's not to like.
Posted at 23/1/2023 15:16 by pwhite73
Rajraj b - "Share price isn’t reacting to the shorters strategy."

That can be credited to one person AS. He has kept the share price bubbling over by his ability to present the very best side of Avacta. The only reason the share price initially collapsed to 48p last year was because he had no control over the approval of the lateral flow test. With AVA6000 he has totally control and has used his skill in wording to give the impression to PI shareholders the development of the drug is heading towards commerciality.

Told you all before look over 18 years of RNS announcements and there is not a single negative one, none whatsoever. The only negative RNS was the one concerning the LFT. However you don't get any wild RNS's today like you did a few years back.

RNS 10 May 2017 - "Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that the principal patent protecting the Affimer technology has been accepted for grant in the People's Republic of China[1]. On issuance, this patent will extend coverage of Avacta's intellectual property into another potentially large market for the Company; considering the therapeutic applications of Affimers alone, China now accounts for more than one fifth of the global therapeutic antibody market[2]."

What happened to that development. Had I been around at the time I would have told investors that China does not recognise western patents.

Posted at 11/1/2023 17:12 by pwhite73
tickboo - "I expect they had the data on 19 Dec"

I believe you are correct and indeed I suspect they've been sitting on this information for months. The question for them is when is the best time to release the information if at all. With the share price gaining traction since 19 Dec announcement there is no need for them to release any information just yet. That's the game this company plays and in doing so shareholders like yourself are always forced to say, "over the coming weeks, its the content that really matters".

It is only the upcoming conversions that has forced them to consider buttressing the share price with the potential release of Phase 1a data. This is why I say to you if the share price holds up prior to conversion you may not get any news at all as the Phase 1 trial is not officially due for completion until June 2023.

Posted at 09/1/2023 14:57 by rajraj b
Share price should continue upwards as everybody is awaiting news that could drop anytime. The closer we get to the end of the week with no news, the higher the share price will accelerate. If the news was poor, I'm sure management would have had to disclose this by now. They certainly wouldn't announce a Science day meeting for Fund Managers and world leading oncologists. Yet, this is exactly what they have done.
Posted at 09/1/2023 10:48 by pwhite73
tickboo - "Indeed. One user logged in at a time. It is not a difficult concept."

Yes but they would all need to know the password. This would require the user who is paying for the blue validated status sharing his password with others for free unless they are all chipping in to pay for the premium service.

I am not saying there will be no RNS. What I'm saying is historically there is plenty of evidence to show that when the share price is rising the company will do nothing to rock the boat. People were anticipating an RNS 07:00 today or later that's why the share price is rising. Consequently historically speaking that's why there will be no RNS today and probably no RNS tomorrow either if the share price ends blue.

Posted at 09/1/2023 10:14 by pwhite73
You also have to contemplate the fact that whilst the share price is rising in anticipation of a PK data RNS there will be no RNS. That's the way this company operates. If the share price is rising then STFU.
Posted at 07/12/2022 16:20 by tickboo
I hope Avacta and I am not on this BB in 10 months let alone years!! If P1a data is poor the share price will crash. No question. If the P1a data is positive but lacking efficacy info so without biopsies we will do okay and likely have to await other news for a real share price appreciation. If data is positive and is data rich including biopsies which demonstrate efficacy as Dox in the tumour and no DLTs the share price will surely fly. Not only that I would think Avacta will be a takeover target and given the swelling balance sheets of majors I suspect there will be a good few vying.
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230207 21:45:03